Regeneron Pharmaceuticals (NASDAQ:REGN) Given “Buy” Rating at Truist Financial

Truist Financial reissued their buy rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $1,200.00 target price on the biopharmaceutical company’s stock.

A number of other research firms also recently weighed in on REGN. Leerink Partners reissued a market perform rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday. Barclays boosted their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an overweight rating in a research report on Friday, August 2nd. TD Cowen boosted their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a buy rating in a report on Tuesday, July 23rd. Royal Bank of Canada restated an outperform rating and set a $1,282.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 17th. Finally, Wells Fargo & Company reaffirmed an overweight rating and set a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, September 23rd. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $1,118.62.

Regeneron Pharmaceuticals Trading Up 0.3 %

NASDAQ REGN opened at $1,042.69 on Tuesday. Regeneron Pharmaceuticals has a 12 month low of $769.19 and a 12 month high of $1,211.20. The stock’s fifty day moving average price is $1,129.33 and its 200-day moving average price is $1,034.03. The stock has a market cap of $114.89 billion, a P/E ratio of 31.20, a P/E/G ratio of 3.72 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter in the previous year, the business earned $8.79 earnings per share. The company’s revenue was up 12.3% on a year-over-year basis. As a group, equities analysts forecast that Regeneron Pharmaceuticals will post 37.8 EPS for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. The disclosure for this sale can be found here. Insiders sold a total of 9,270 shares of company stock valued at $10,695,833 over the last three months. 7.48% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Sachetta LLC grew its position in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the period. Stephens Consulting LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $26,000. West Paces Advisors Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares during the last quarter. Crewe Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $28,000. Finally, Lynx Investment Advisory purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.